View Item 

Show simple item record

A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma

dc.contributor.authorHussain, Mahaen_US
dc.contributor.authorDaignault, Stephanieen_US
dc.contributor.authorAgarwal, Neerajen_US
dc.contributor.authorGrivas, Petros D.en_US
dc.contributor.authorSiefker‐radtke, Arlene O.en_US
dc.contributor.authorPuzanov, Igoren_US
dc.contributor.authorMacVicar, Gary R.en_US
dc.contributor.authorLevine, Ellis Glennen_US
dc.contributor.authorSrinivas, Sandyen_US
dc.contributor.authorTwardowski, Przemyslawen_US
dc.contributor.authorEisenberger, Mario A.en_US
dc.contributor.authorQuinn, David I.en_US
dc.contributor.authorVaishampayan, Ulka N.en_US
dc.contributor.authorYu, Evan Y.en_US
dc.contributor.authorDawsey, Scotten_US
dc.contributor.authorDay, Kathleen C.en_US
dc.contributor.authorDay, Mark L.en_US
dc.contributor.authorAl‐hawary, Mahmouden_US
dc.contributor.authorSmith, David C.en_US
dc.date.accessioned2014-09-03T16:52:17Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-09-03T16:52:17Z
dc.date.issued2014-09-01en_US
dc.identifier.citationHussain, Maha; Daignault, Stephanie; Agarwal, Neeraj; Grivas, Petros D.; Siefker‐radtke, Arlene O. ; Puzanov, Igor; MacVicar, Gary R.; Levine, Ellis Glenn; Srinivas, Sandy; Twardowski, Przemyslaw; Eisenberger, Mario A.; Quinn, David I.; Vaishampayan, Ulka N.; Yu, Evan Y.; Dawsey, Scott; Day, Kathleen C.; Day, Mark L.; Al‐hawary, Mahmoud ; Smith, David C. (2014). "A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma." Cancer 120(17): 2684-2693.en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/108368
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherGemcitabineen_US
dc.subject.otherChemotherapyen_US
dc.subject.otherUrothelial Carcinomaen_US
dc.subject.otherCisplatinen_US
dc.subject.otherCetuximaben_US
dc.titleA randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinomaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/108368/1/cncr28767.pdf
dc.identifier.doi10.1002/cncr.28767en_US
dc.identifier.sourceCanceren_US
dc.identifier.citedreferencePhilips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol. 2009; 20: 1074 ‐ 1079.en_US
dc.identifier.citedreferencePerrotte P, Matsumoto T, Inoue K, et al. Anti‐epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 1999; 5: 257 ‐ 265.en_US
dc.identifier.citedreferenceBlack PC, Brown GA, Inamoto T, et al. Sensitivity to epidermal growth factor receptor inhibitor requires E‐cadherin expression in urothelial carcinoma cells. Clin Cancer Res. 2008; 14: 1478 ‐ 1486.en_US
dc.identifier.citedreferenceGrabowska MM, Sandhu B, Day ML. EGF promotes the shedding of soluble E‐cadherin in an ADAM10‐dependent manner in prostate epithelial cells. Cell Signal. 2012; 24: 532 ‐ 538.en_US
dc.identifier.citedreferenceZuo JH, Zhu W, Li MY, et al. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT‐like phenotype change and MMP‐9‐mediated degradation of E‐cadherin. J Cell Biochem. 2011; 112: 2508 ‐ 2517.en_US
dc.identifier.citedreferenceTherasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205 ‐ 216.en_US
dc.identifier.citedreferenceSimon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep. 1985; 69: 1375 ‐ 1381.en_US
dc.identifier.citedreferenceBotten J, Sephton M, Tillett T, et al. Thromboembolic events with cisplatin‐based neoadjuvant chemotherapy for transitional cell carcinoma of urinary bladder. J Clin Oncol. 2013; 31 ( suppl 6 ): 277.en_US
dc.identifier.citedreferencePessino A, Artale S, Sciallero S, et al. First‐line single‐agent cetuximab in patients with advanced colorectal cancer. Ann Oncol. 2008; 19: 711 ‐ 716.en_US
dc.identifier.citedreferencePetrelli F, Cabiddu M, Borgonovo K, et al. Risk of venous and arterial thromboembolic events associated with anti‐EGFR agents: a meta‐analysis of randomized clinical trials. Ann Oncol. 2012; 23: 1672 ‐ 1679.en_US
dc.identifier.citedreferenceHahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first‐line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04‐75. J Clin Oncol. 2011; 29: 1525 ‐ 1530.en_US
dc.identifier.citedreferenceRoss J, Wang K, Al‐Rohil RN, et al. Advanced urothelial carcinoma: next‐generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol. 2014; 27: 271 ‐ 280.en_US
dc.identifier.citedreferenceIyer G, Al‐Ahmadie H, Schultz N, et al. Prevalence and co‐occurrence of actionable genomic alterations in high‐grade bladder cancer. J Clin Oncol. 2013; 31: 3133 ‐ 3140.en_US
dc.identifier.citedreferenceWong YN, Litwin S, Vaughn D, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol. 2012; 30: 3545 ‐ 3551.en_US
dc.identifier.citedreferenceWulfing C, Machiels JP, Richel DJ, et al. A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 2009; 115: 2881 ‐ 2890.en_US
dc.identifier.citedreferencePetrylak DP, Tangen CM, Van Veldhuizen PJ Jr, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int. 2010; 105: 317 ‐ 321.en_US
dc.identifier.citedreferenceWheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008; 27: 3944 ‐ 3956.en_US
dc.identifier.citedreferenceTsai YS, Cheng HL, Tzai TS, et al. Clinical significance of ErbB receptor family in urothelial carcinoma of the bladder: a systematic review and meta‐analysis. Adv Urol. 2012; 2012: 181964.en_US
dc.identifier.citedreferenceGrivas PD, Day KC, Karatsinides A, et al. Evaluation of the anti‐tumor activity of dacomitinib in models of human bladder cancer. Mol Med. 2013; 19: 367 ‐ 376.en_US
dc.identifier.citedreferenceFigueroa JD, Ye Y, Siddiq A, et al. Genome‐wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet. 2014; 23: 1387 ‐ 1398.en_US
dc.identifier.citedreferenceSolomon DA, Kim JS, Bondaruk J, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet. 2013; 45: 1428 ‐ 1423.en_US
dc.identifier.citedreferenceGuo G, Sun X, Chen C, et al. Whole‐genome and whole‐exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet. 2013; 45: 1459 ‐ 1463.en_US
dc.identifier.citedreferenceRoss JS, Wang K, Gay L, et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res. 2014; 20: 68 ‐ 75.en_US
dc.identifier.citedreferenceOmran OM. CD10 and E‐cad expression in urinary bladder urothelial and squamous cell carcinoma. J Environ Pathol Toxicol Oncol. 2012; 31: 203 ‐ 212.en_US
dc.identifier.citedreferenceReis ST, Leite KR, Mosconi Neto A, et al. Immune expression of E‐cadherin and α, β and γ‐catenin adhesion molecules and prognosis for upper urinary tract urothelial carcinomas. Int Braz J Urol. 2012; 38: 466 ‐ 473.en_US
dc.identifier.citedreferenceKhorrami MH, Hadi M, Gharaati MR, et al. E‐cadherin expression as a prognostic factor in transitional cell carcinoma of the bladder after transurethral resection. Urol J. 2012; 9: 581 ‐ 585.en_US
dc.identifier.citedreferenceCui D, Han BM, Jing YF, et al. Analysis of N‐E cadherin switch as an independent predictive parameter of bladder cancer survival outcomes [in Chinese]. Zhonghua Yi Xue Za Zhi. 2012; 92: 380 ‐ 383.en_US
dc.identifier.citedreferenceMuramaki M, Miyake H, Terakawa T, et al. Expression profile of E‐cadherin and N‐cadherin in non‐muscle‐invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. Urol Oncol. 2012; 30: 161 ‐ 166.en_US
dc.identifier.citedreferenceErdemir F, Ozcan F, Kilicaslan I, et al. The relationship between the expression of E‐cadherin and tumor recurrence and progression in high‐grade stage T1 bladder urothelial carcinoma. Int Urol Nephrol. 2007; 39: 1031 ‐ 1037.en_US
dc.identifier.citedreferenceByrne RR, Shariat SF, Brown R, et al. E‐cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long‐term followup. J Urol. 2001; 165: 1473 ‐ 1479.en_US
dc.identifier.citedreferenceHu X, Ruan Y, Cheng F, et al. p130Cas, E‐cadherin and β‐catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance. Int J Urol. 2011; 18: 630 ‐ 637.en_US
dc.identifier.citedreferenceShariat SF, Pahlavan S, Baseman AG, et al. E‐cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001; 57: 60 ‐ 65.en_US
dc.identifier.citedreferenceSerdar A, Turhan C, Soner G, et al. The prognostic importance of e‐cadherin and p53 gene expression in transitional bladder carcinoma patients. Int Urol Nephrol. 2005; 37: 485 ‐ 492.en_US
dc.identifier.citedreferenceMahnken A, Kausch I, Feller AC, et al. E‐cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder. Oncol Rep. 2005; 14: 1065 ‐ 1070.en_US
dc.identifier.citedreferenceFromont G, Roupret M, Amira N, et al. Tissue microarray analysis of the prognostic value of E‐cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol. 2005; 48: 764 ‐ 770.en_US
dc.identifier.citedreferenceKashibuchi K, Tomita K, Schalken JA, et al. The prognostic value of E‐cadherin, alpha‐, beta‐, and gamma‐catenin in urothelial cancer of the upper urinary tract. Eur Urol. 2006; 49: 839 ‐ 845.en_US
dc.identifier.citedreferenceMialhe A, Louis J, Montlevier S, et al. Expression of E‐cadherin and alpha‐, beta‐ and gamma‐catenins in human bladder carcinomas: are they good prognostic factors? Invasion Metastasis. 1997; 17: 124 ‐ 137.en_US
dc.identifier.citedreferenceMatsumoto K, Shariat SF, Casella R, et al. Preoperative plasma soluble E‐cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol. 2003; 170 ( pt 1 ): 2248 ‐ 2252.en_US
dc.identifier.citedreferencevon der Maase H, Sengelov L, Roberts JT, et al. Long‐term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 4602 ‐ 4608.en_US
dc.identifier.citedreferenceNicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001; 37: S9 ‐ S15.en_US
dc.identifier.citedreferenceChow NH, Liu HS, Lee EI, et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res. 1997; 17: 1293 ‐ 1296.en_US
dc.identifier.citedreferenceSalomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor‐related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19: 183 ‐ 232.en_US
dc.identifier.citedreferenceWells A. Tumor invasion: role of growth factor‐induced cell motility. Adv Cancer Res. 2000; 78: 31 ‐ 101.en_US
dc.identifier.citedreferenceEccles SA. Cell biology of lymphatics metastasis. The potential role of c‐erbB oncogene signaling. Recent Results Cancer Res. 2000; 157: 41 ‐ 54.en_US
dc.identifier.citedreferenceNguyen PL, Swanson PE, Jaszcz W, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol. 1994; 101: 166 ‐ 176.en_US
dc.identifier.citedreferenceNeal DE, Marsh C, Bennett MK, et al. Epidermal‐growth‐factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet. 1985; 1: 366 ‐ 368.en_US
dc.identifier.citedreferenceNeal DE, Sharples L, Smith K, et al. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer. 1990; 65: 1619 ‐ 1625.en_US
dc.identifier.citedreferenceMessing EM. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res. 1990; 50: 2530 ‐ 2537.en_US
dc.identifier.citedreferenceBue P, Wester K, Sjostrom A, et al. Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer. 1998; 76: 189 ‐ 193.en_US
dc.identifier.citedreferenceLipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c‐erbB‐2, p53) expression and long‐term prognosis. Br J Cancer. 1994; 69: 1120 ‐ 1125.en_US
dc.identifier.citedreferenceKramer C, Klasmeyer K, Bojar H, et al. Heparin‐binding epidermal growth factor‐like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer. 2007; 109: 2016 ‐ 2024.en_US
dc.identifier.citedreferenceMellon K, Wright C, Kelly P, et al. Long‐term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol. 1995; 153: 919 ‐ 925.en_US
dc.identifier.citedreferenceKroft SH, Oyasu R. Urinary bladder cancer: mechanisms of development and progression. Lab Invest. 1994; 71: 158 ‐ 174.en_US
dc.identifier.citedreferenceBos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989; 49: 4682 ‐ 4689.en_US
dc.identifier.citedreferenceKompier LC, Lurkin I, van der Aa MN, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010; 5: e13821.en_US
dc.identifier.citedreferenceVisvanathan KV, Pocock RD, Summerhayes IC. Preferential and novel activation of H‐ras in human bladder carcinomas. Oncogene Res. 1988; 3: 77 ‐ 86.en_US
dc.identifier.citedreferenceKarimianpour N, Mousavi‐Shafaei P, Ziaee AA, et al. Mutations of RAS gene family in specimens of bladder cancer. Urol J. 2008; 5: 237 ‐ 242.en_US
dc.identifier.citedreferenceMunk M, Memon AA, Nexo E, et al. Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA‐damaging drug etoposide markedly increases apoptosis. BJU Int. 2007; 99: 196 ‐ 201.en_US
dc.identifier.citedreferenceMcHugh LA, Kriajevska M, Mellon JK, et al. Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens—evidence of schedule‐dependent synergy. Urology. 2007; 69: 390 ‐ 394.en_US
dc.identifier.citedreferenceBonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. N Engl J Med. 2006; 354: 567 ‐ 578.en_US
dc.identifier.citedreferenceCunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan‐refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337 ‐ 345.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr28767.pdf
Size:
361.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.